Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA).

JAMA dermatology - 1 Jan 2017

Cordoro Kelly M, Ucmak Derya, Hitraya-Low Maria, Rosenblum Michael D, Liao Wilson

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Drug Therapy, Combination
Share to Injections, Subcutaneous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin 1 Receptor Antagonist Protein

Share to Interleukin-17

Share to Interleukins

Share to Psoriasis

Source

Identifiers

PMID: 27760239
DOI: 10.1001/jamadermatol.2016.3490

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA).PMID 27760239Read ↗

Cutaneous findings and treatments in deficiency of interleukin-36 receptor antagonist (DITRA): A review of the literature.Semantic proximity Read ↗

Deficiency of the interleukin-36 receptor antagonist dramatically improved by secukinumab.Semantic proximity Read ↗

SARS-CoV-2 infection inducing severe flare up of Deficiency of Interleukin Thirty-six (IL-36) Receptor Antagonist (DITRA) resulting from a mutation invalidating the activating cleavage site of the IL-36 receptor antagonist.Semantic proximity Read ↗

Analysis of Anakinra therapy for the Deficiency of Interleukin-1 Receptor Antagonist through Clinical EvidenceSemantic proximity Read ↗

Molecular determinants of agonist and antagonist signaling through the IL-36 receptor.Semantic proximity Read ↗

Decreased cellular IL-23 but not IL-17 production in children with autism spectrum disordersSemantic proximity Read ↗

Extending the clinical and immunological phenotype of human interleukin-21 receptor deficiency.Semantic proximity Read ↗

IL-4Rα Inhibitor for Atopic DiseaseSemantic proximity Read ↗

Novel inflammatory targets for immunotherapies in pediatric patients with trichotillomania.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.